ATE445397T1 - N-hydroxy-4-ä5-ä4-(5-isopropyl-2-methyl-1,3- thiazol-4-yl)phenoxyüpentoxyübenzamidin 2 methansulfonsauresalz - Google Patents

N-hydroxy-4-ä5-ä4-(5-isopropyl-2-methyl-1,3- thiazol-4-yl)phenoxyüpentoxyübenzamidin 2 methansulfonsauresalz

Info

Publication number
ATE445397T1
ATE445397T1 AT05817697T AT05817697T ATE445397T1 AT E445397 T1 ATE445397 T1 AT E445397T1 AT 05817697 T AT05817697 T AT 05817697T AT 05817697 T AT05817697 T AT 05817697T AT E445397 T1 ATE445397 T1 AT E445397T1
Authority
AT
Austria
Prior art keywords
thiazol
isopropyl
hydroxy
methyl
salt
Prior art date
Application number
AT05817697T
Other languages
English (en)
Inventor
Jei Ryu
Jin Lee
Dong Shin
Seung Seong
Soon Cho
Chan Jeon
Young Jin
Ki Lee
Se Jung
Eun Cho
Seok Hoon Ahn
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE445397(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Application granted granted Critical
Publication of ATE445397T1 publication Critical patent/ATE445397T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT05817697T 2004-11-23 2005-11-22 N-hydroxy-4-ä5-ä4-(5-isopropyl-2-methyl-1,3- thiazol-4-yl)phenoxyüpentoxyübenzamidin 2 methansulfonsauresalz ATE445397T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040096390 2004-11-23
PCT/KR2005/003934 WO2006057501A1 (en) 2004-11-23 2005-11-22 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt

Publications (1)

Publication Number Publication Date
ATE445397T1 true ATE445397T1 (de) 2009-10-15

Family

ID=36498212

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05817697T ATE445397T1 (de) 2004-11-23 2005-11-22 N-hydroxy-4-ä5-ä4-(5-isopropyl-2-methyl-1,3- thiazol-4-yl)phenoxyüpentoxyübenzamidin 2 methansulfonsauresalz

Country Status (18)

Country Link
US (2) US20090176846A1 (de)
EP (2) EP1701722B1 (de)
JP (2) JP4774053B2 (de)
KR (2) KR101047042B1 (de)
CN (3) CN101693029B (de)
AT (1) ATE445397T1 (de)
AU (2) AU2005300239B2 (de)
BR (2) BRPI0517396A (de)
CA (2) CA2552766C (de)
DE (1) DE602005017118D1 (de)
DK (1) DK1701722T3 (de)
ES (1) ES2333739T3 (de)
IL (2) IL180985A (de)
NZ (1) NZ555725A (de)
PT (1) PT1701722E (de)
RU (1) RU2361867C2 (de)
WO (2) WO2006057507A1 (de)
ZA (2) ZA200700485B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997367B (zh) * 2004-07-05 2010-11-24 同和药品株式会社 预防和治疗过敏性炎症的组合物
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
RU2361867C2 (ru) * 2004-11-23 2009-07-20 Донг Вха Фармасьютикал. Инд. Ко., Лтд. Диметансульфонат n-гидрокси-4{5-[4-(5-изопропил-2-метил-1, 3-тиазол-4-ил)фенокси]пентокси}бензамидина
MX2009010339A (es) * 2007-04-19 2009-10-16 Dong Wha Pharm Co Ltd Sal del acido 2-etanosulfonico de n-hidroxi-4{5-[4-(5-isopropil-2- metil-1,3-tiazol-4-il)fenoxi]pentoxi} benzamidina, procedimiento para su preparacion, y composicion farmaceutica que comprende la misma.
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
HRP20190186T4 (hr) † 2011-07-28 2024-12-20 Rigel Pharmaceuticals, Inc. Nove formulacije (trimetoksifenilamino)pirimidinila
JP6292744B2 (ja) * 2012-09-19 2018-03-14 富士カプセル株式会社 医薬品組成物
WO2014119767A1 (ja) * 2013-01-31 2014-08-07 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP6680297B2 (ja) 2015-04-28 2020-04-15 アステラス製薬株式会社 経口投与用医薬組成物
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
TW201912157A (zh) 2017-08-18 2019-04-01 美商艾伯維有限公司 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物
CN111698992A (zh) * 2017-08-18 2020-09-22 艾伯维公司 用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合症或子宫腺肌症的药物配制物
KR102276547B1 (ko) * 2020-09-04 2021-07-13 주식회사유한양행 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5091191A (en) * 1988-02-03 1992-02-25 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition with improved dissolution property
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
CA2427890A1 (en) * 1992-02-05 1993-08-19 Ralf Anderskewitz New amidine derivatives, the preparation and use thereof
DE4424713A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Substituierte Benzamidine, ihre Herstellung und Verwendung als Arnzneistoffe
PA8441701A1 (es) * 1996-11-26 2000-05-24 Pfizer Sales dimesilato de los ligandos del neuropeptido y
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
HK1047431B (en) * 1999-10-28 2006-07-14 三共株式会社 Benzamidine derivatives
KR100454767B1 (ko) * 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
KR100789567B1 (ko) * 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
WO2003075884A1 (en) * 2002-03-06 2003-09-18 Lifizz, Inc. Effervescent compositions comprising bisphosphonates and methods related thereto
AU2003216581A1 (en) * 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
WO2003101431A1 (en) 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
CN100342860C (zh) * 2003-03-18 2007-10-17 兴和株式会社 抗酸剂组合物
RU2361867C2 (ru) * 2004-11-23 2009-07-20 Донг Вха Фармасьютикал. Инд. Ко., Лтд. Диметансульфонат n-гидрокси-4{5-[4-(5-изопропил-2-метил-1, 3-тиазол-4-ил)фенокси]пентокси}бензамидина

Also Published As

Publication number Publication date
CA2585003A1 (en) 2006-06-01
CN101056658A (zh) 2007-10-17
JP4774053B2 (ja) 2011-09-14
CN101693029B (zh) 2011-11-02
BRPI0514386B1 (pt) 2021-02-09
IL180985A (en) 2012-02-29
JP2008508264A (ja) 2008-03-21
EP1701722A4 (de) 2007-05-16
KR20060057514A (ko) 2006-05-26
AU2005307994B2 (en) 2009-07-23
PT1701722E (pt) 2009-12-10
CA2552766C (en) 2010-08-17
US20090176846A1 (en) 2009-07-09
JP2008520655A (ja) 2008-06-19
KR20060057511A (ko) 2006-05-26
BRPI0514386B8 (pt) 2021-05-25
WO2006057501A1 (en) 2006-06-01
ZA200704236B (en) 2008-11-26
BRPI0517396A (pt) 2008-10-14
CN100574756C (zh) 2009-12-30
AU2005300239B2 (en) 2009-08-06
US20070254930A1 (en) 2007-11-01
ZA200700485B (en) 2007-11-28
CA2585003C (en) 2010-08-17
IL182647A0 (en) 2007-07-24
NZ555725A (en) 2008-07-31
RU2361867C2 (ru) 2009-07-20
HK1094530A1 (en) 2007-04-04
CN1905871B (zh) 2010-07-07
WO2006057507A1 (en) 2006-06-01
AU2005300239A1 (en) 2006-07-06
CN1905871A (zh) 2007-01-31
BRPI0514386A (pt) 2008-06-10
CN101693029A (zh) 2010-04-14
JP4773456B2 (ja) 2011-09-14
EP1814593A1 (de) 2007-08-08
RU2007123614A (ru) 2008-12-27
EP1701722A1 (de) 2006-09-20
IL180985A0 (en) 2007-07-04
KR101047042B1 (ko) 2011-07-06
KR100716389B1 (ko) 2007-05-11
DK1701722T3 (da) 2010-01-11
CA2552766A1 (en) 2006-06-01
IL182647A (en) 2011-04-28
AU2005307994A1 (en) 2006-06-01
ES2333739T3 (es) 2010-02-26
EP1814593A4 (de) 2012-09-05
DE602005017118D1 (de) 2009-11-26
EP1701722B1 (de) 2009-10-14

Similar Documents

Publication Publication Date Title
IL180985A0 (en) N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methanesulfonic acid salt
WO2009025983A3 (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
CL2008002142A1 (es) Compuestos derivados de 2-amino-6-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}tio)-4-[4-(2-hidroxietoxi) fenil] piridin-3,5-dicarbonitrilo; procedimiento de preparacion; composicion farmaceutica y uso en enfermedades cardiovasculares.
CY1107238T1 (el) Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης
PE20070351A1 (es) N-[2-[haloalcoxi)fenil]heteroarilcarboxamidas fungicidas
WO2008126899A1 (ja) ５員環へテロ環誘導体及びその医薬用途
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
WO2008104847A3 (en) Processes for the preparation of pramipexole and salts thereof
CY1125531T1 (el) Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων της
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
UA92354C2 (en) Amino acid salts of rosiglitazone
WO2006003471A3 (en) Process for the preparation of pramipexole by chiral chromatography
NZ598754A (en) Therapeutic agent for anxiety disorders
EP1837329A4 (de) Neues heteroarylderivat
WO2009012201A3 (en) Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides
WO2005012273A3 (en) Process for the preparation of substituted thiazoles
BRPI0607085A2 (pt) derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
AU2003269483A1 (en) Phosphoric acid salt of 5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)- 2,4-thiazolidinedione
ATE469156T1 (de) 3,4 diaminopyridin-derivate
ATE425162T1 (de) Thiazolderivate als npy-antagonisten
EP1403260A3 (de) Optisch aktive Epoxyverbindungen und Verfahren zu deren Herstellung
BRPI0513034A (pt) processo aperfeiçoado para preparação de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1, 3-tiazol-4-il)-fenóxi]-pentóxi}-benzamidina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1701722

Country of ref document: EP